Menu
Search
|

Menu

Close
X

Kalvista Pharmaceuticals Inc KALV.OQ (NASDAQ Stock Exchange Global Market)

8.58 USD
+0.10 (+1.18%)
As of Jul 18
chart
Previous Close 8.48
Open 8.53
Volume 1,391
3m Avg Volume 5,346
Today’s High 8.94
Today’s Low 8.53
52 Week High 15.75
52 Week Low 5.48
Shares Outstanding (mil) 10.80
Market Capitalization (mil) 91.66
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.491
FY17
-1.438
FY16
-8.687
FY15
-15.811
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.89
Price to Sales (TTM)
vs sector
24.99
8.00
Price to Book (MRQ)
vs sector
3.21
4.21
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
1.19
17.41
LT Debt to Equity (MRQ)
vs sector
0.41
13.26
Return on Investment (TTM)
vs sector
-49.99
13.14
Return on Equity (TTM)
vs sector
-61.02
15.15

EXECUTIVE LEADERSHIP

Richard Aldrich
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Thomas Crockett
Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
Benjamin Palleiko
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Christopher Yea
Chief Development Officer, Since 2016
Salary: --
Bonus: --
Arnold Oronsky
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Building 200, 1 Kendall Sq Ste 2
CAMBRIDGE   MA   02139-1562

Phone: +1857.9990075

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

SPONSORED STORIES